Patent application number | Description | Published |
20090246131 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies - The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them. | 10-01-2009 |
20100074840 | Anthracycline-Antibody Conjugates for Cancer Therapy - The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety. | 03-25-2010 |
20100136626 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies - The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them. | 06-03-2010 |
20100158803 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies - The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them. | 06-24-2010 |
20110070155 | Anti-CD74 Immunoconjugates and Methods - Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods. | 03-24-2011 |
20120309045 | Composite Probes and Use Thereof in Super Resolution Methods - Composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ) include a donor moiety and an acceptor moiety joined by a linker, wherein the acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification and/or nanoscale chemical reactions. | 12-06-2012 |
20130095034 | Anti-CD74 Immunoconjugates and Methods - Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods. | 04-18-2013 |
20130171176 | Anthracycline-Antibody Conjugates for Cancer Therapy - The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety. | 07-04-2013 |
20130345391 | Composite Probes and Use Thereof in Super Resolution Methods - Composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ) include a donor moiety and an acceptor moiety joined by a linker, wherein the acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification and/or nanoscale chemical reactions. | 12-26-2013 |
20140154273 | Anthracycline-Antibody Conjugates for Cancer Therapy - The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety. | 06-05-2014 |
Patent application number | Description | Published |
20080281271 | DRUG DELIVERY SYSTEM WITH A SMALL AMOUNT OF A THERAPEUTIC AGENT - A drug delivery system includes an automatic injector that can deliver a small, precise amount of a therapeutic agent. The automatic injector includes a chamber for containing a liquid component and a thin porous member that carries thereon and/or therein the small, precise amount of therapeutic agent. Upon activation of the automatic injector, a flow path opens from the chamber through the porous member, enabling the liquid component to rapidly mix with the therapeutic agent before being injected. | 11-13-2008 |
20090205744 | METHODS OF FORMING A NEEDLE AND HUB ASSEMBLY FOR AUTOMATIC INJECTORS - A needle and hub assembly for automatic injectors includes a cap or skirt that has a forward surface interposed between and reinforced by first and second engaged hub portions. A needle is received in a contiguous channel formed in the two hub portions. Methods of forming the assembly include molding the first hub portion, placing the cap over the first hub portion, inserting the needle into the channel in the first hub portion, and then overmolding or otherwise forming the second hub portion on the exterior of the first hub portion and cap such that the second hub portion engages the first hub portion. An assembly created by this “two-shot” process can be used to seal a relatively large opening in a medicament cartridge and to support the needle more effectively than a conventional assembly. | 08-20-2009 |
20100228190 | SEAL STRUCTURES FOR WET/DRY AUTOMATIC INJECTORS - An automatic medicament injector has a first compartment for a first medicament component and a second compartment for a second medicament component. The two compartments are separated by a seal structure that converts from a sealing condition to a mixing condition when the device is activated. The seal structure has a plug that opens a flow path through the seal structure to allow the second medicament component to mix with the first medicament component in the first compartment when the seal structure is in the mixing condition. | 09-09-2010 |